PT94992A - New interleukin-3 mutants - having deletions covering complete coding sequence while retaining biological activity, have antagonistic effect - Google Patents

New interleukin-3 mutants - having deletions covering complete coding sequence while retaining biological activity, have antagonistic effect

Info

Publication number
PT94992A
PT94992A PT199094992A PT9499290A PT94992A PT 94992 A PT94992 A PT 94992A PT 199094992 A PT199094992 A PT 199094992A PT 9499290 A PT9499290 A PT 9499290A PT 94992 A PT94992 A PT 94992A
Authority
PT
Portugal
Prior art keywords
mutants
deletion
residues
coding sequence
biological activity
Prior art date
Application number
PT199094992A
Other languages
Portuguese (pt)
Other versions
PT94992B (en
Inventor
Christiaan Joannes Dorssers Lambertus
Willem Van Leen Robert
Original Assignee
Gist Brocades Nv.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26121243&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT94992(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gist Brocades Nv. filed Critical Gist Brocades Nv.
Publication of PT94992A publication Critical patent/PT94992A/en
Publication of PT94992B publication Critical patent/PT94992B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Abstract

Biologically active polypeptide analogue (A) of human IL-3 comprises a deletion of at least 2 residues compared with mature human IL-3. The deletion comprises an N-terminal deletion of upto 14 residues and/or a C-terminal deletion of upto 18 amino acids. Pref. mutants are the substn. mutants; having following substitution(s); Asp21 Glu22 = Lys21 Arg22, Asp36 = Arg36, Glu43 = Asp44Asp44 = Lys43 Arg44, Arg54 Arg55 = Glu54 Asp55, Asp46= Lys46 or Arg46, Glu50 = Lys50 or Arg 50, Glu59 = Lys59 or Pro59 (alpha-helix breaker), Arg63 Ala64 = Pro63 Gly64, Glu75 = Arg75 or Gly75, Lys79 = Glu79, Arg94 = Pro94, His98 Lys100 Asp 101 = Glu98 Asp100 Gln101, Glu106 = Lys106, Arg108 Arg109 Arg110 = Glu108 Asp109 Glu110, Phe113 Try114 = Ala113 Thr114, Cys16 = Ala16, Cys84 = Ala84 or Cys16 Cys84 = Ala16 Ala84. Also claimed are: (1) a DNA fragment (I) contg. a sequence encoding (A); (2) a cloning vehicle contg. (I); (3) a host cell transformed with the vehicle of (2); (4) a process for obtaining (A); and (5) a monoclonal antibody (MAb) directed against an epitope between residues 29 - 34, of mature human IL-3.
PT94992A 1989-08-14 1990-08-14 METHOD FOR THE PREPARATION OF INTERLEUCIN-3-HUMAN MUTANT POLIPEPTIDES PT94992B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP89202082 1989-08-14
EP89202331 1989-09-14

Publications (2)

Publication Number Publication Date
PT94992A true PT94992A (en) 1991-04-18
PT94992B PT94992B (en) 1997-09-30

Family

ID=26121243

Family Applications (1)

Application Number Title Priority Date Filing Date
PT94992A PT94992B (en) 1989-08-14 1990-08-14 METHOD FOR THE PREPARATION OF INTERLEUCIN-3-HUMAN MUTANT POLIPEPTIDES

Country Status (17)

Country Link
EP (2) EP0413383B1 (en)
JP (1) JP3192416B2 (en)
AT (1) ATE154638T1 (en)
AU (1) AU636641B2 (en)
CA (1) CA2023246C (en)
DD (1) DD301724A9 (en)
DE (1) DE69030937T2 (en)
DK (1) DK0413383T3 (en)
ES (1) ES2106017T3 (en)
FI (1) FI105192B (en)
GR (1) GR3024679T3 (en)
HU (1) HUT54411A (en)
IE (2) IE980055A1 (en)
IL (1) IL95350A0 (en)
NO (1) NO301481B1 (en)
NZ (1) NZ234869A (en)
PT (1) PT94992B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2120707A1 (en) * 1991-10-07 1993-04-15 Mathew A. Vadas Human il-3 variants
US6057133A (en) * 1992-11-24 2000-05-02 G. D. Searle Multivariant human IL-3 fusion proteins and their recombinant production
US6413509B1 (en) 1992-11-24 2002-07-02 S. Christopher Bauer Methods of ex-vivo expansion of hematopoietic cells using interleukin-3 mutant polypeptides with other hematopoietic growth factors
US5738849A (en) * 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US6361976B1 (en) 1992-11-24 2002-03-26 S. Christopher Bauer Co-administration of interleukin-3 mutant polypeptides with CSF'S for multi-lineage hematopoietic cell production
AU690088B2 (en) 1992-11-24 1998-04-23 G.D. Searle & Co. Interleukin-3 (IL-3) multiple mutation polypeptides
US6153183A (en) * 1992-11-24 2000-11-28 G. D. Searle & Company Co-administration of interleukin-3 mutant polypeptides with CSF's or cytokines for multi-lineage hematopoietic cell production
US6403076B1 (en) 1992-11-24 2002-06-11 S. Christopher Bauer Compositions for increasing hematopoiesis with interleukin-3 mutants
US6361977B1 (en) * 1992-11-24 2002-03-26 S. Christopher Bauer Methods of using multivariant IL-3 hematopoiesis fusion protein
US5772992A (en) * 1992-11-24 1998-06-30 G.D. Searle & Co. Compositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factors
US5501962A (en) * 1993-06-21 1996-03-26 G. D. Searle & Co. Interleuken-3 (IL-3) human/murine hybrid polypeptides and recombinant production of the same
NZ269766A (en) * 1993-07-28 1998-01-26 Medvet Science Pty Ltd Haemopoietic growth factor antagonists; relates to modified forms of such factors
US6465616B1 (en) 1994-04-08 2002-10-15 Bresagen Limited Interleukin-5 antagonist
US6017523A (en) * 1995-06-06 2000-01-25 G.D. Searle & Co. Therapeutic methods employing mutant human interleukin-3 (IL-3) polypeptides
US6270758B1 (en) 1998-10-08 2001-08-07 Duke University Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects
JP4735670B2 (en) * 2008-06-11 2011-07-27 富士ゼロックス株式会社 Printed circuit board and image processing apparatus

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR871029B (en) 1986-07-14 1987-11-02 Genetics Inst Novel osteoinductive factors
PT86381B (en) 1986-12-16 1990-11-20 Gist Brocades Nv MOLECULAR AND EXPRESSION CLONING PROCESS OF HUMAN INTERLEUKIN-3 (IL-3)
EP0790307A1 (en) 1986-12-16 1997-08-20 Gist-Brocades B.V. Molecular cloning and expression of human IL-3
EP0342206A4 (en) 1987-01-20 1990-09-19 Immunex Corporation Human interleukin-3 proteins
US4743264A (en) * 1987-02-05 1988-05-10 Sherva Parker Carole J External prothesis with magnetic field
OA09736A (en) 1987-02-18 1993-11-30 Schering Biotech Corp "Human interleukin-3 and muteins thereof".

Also Published As

Publication number Publication date
IE980055A1 (en) 2000-02-23
EP0413383A1 (en) 1991-02-20
JPH0420295A (en) 1992-01-23
NZ234869A (en) 1991-12-23
GR3024679T3 (en) 1997-12-31
CA2023246C (en) 2002-02-19
FI105192B (en) 2000-06-30
NO903544D0 (en) 1990-08-13
AU6096090A (en) 1991-02-14
ES2106017T3 (en) 1997-11-01
DE69030937T2 (en) 1997-10-09
JP3192416B2 (en) 2001-07-30
EP0413383B1 (en) 1997-06-18
DE69030937D1 (en) 1997-07-24
CA2023246A1 (en) 1991-02-15
ATE154638T1 (en) 1997-07-15
IE902921A1 (en) 1991-02-27
DD301724A9 (en) 1993-08-12
PT94992B (en) 1997-09-30
DK0413383T3 (en) 1997-07-07
IL95350A0 (en) 1991-06-30
EP0810285A2 (en) 1997-12-03
NO903544L (en) 1991-02-15
EP0810285A3 (en) 1998-07-08
HUT54411A (en) 1991-02-28
NO301481B1 (en) 1997-11-03
AU636641B2 (en) 1993-05-06
FI903996A0 (en) 1990-08-13

Similar Documents

Publication Publication Date Title
PT94992A (en) New interleukin-3 mutants - having deletions covering complete coding sequence while retaining biological activity, have antagonistic effect
EP1283264A3 (en) Interleukin-3 (IL-3) mutant polypeptides
CN1294596A (en) Method for reducing immunogenicity of proteins
KR890003802A (en) Bovine pancreatic trypsin inhibitor produced by recombinant DNA technology, methods for preparing the same, expression vectors and recombinant hosts and pharmaceutical uses thereof
GR3034140T3 (en) CD2-Binding domain of lymphocyte function associated antigen 3.
AU5258898A (en) Mutant forms of fas ligand and uses thereof
JP2003530839A5 (en)
AU7565991A (en) Variant cd44 surface proteins, dna sequences coding them, antibodies against these proteins and their use in diagnosis and therapy
DE JONG et al. Primary Structures of the α‐Crystallin A Chains of Seven Mammalian Species
RU93045577A (en) MULTIPLE POLYPEPTIDES
Davis et al. Basic fibroblast growth factor induces 3T3 fibroblasts to synthesize and secrete a cyclophilin-like protein and β2-microglobulin
EP0965637A4 (en) Fas ANTIGEN DERIVATIVES
IE850614L (en) Cloning of interleukin
HUT69169A (en) T-cell-suppressive peptide fragments of human myelin basic protein (hmbp) and pharmaceutical compositions containing them
EP1849870A1 (en) Immunoreactive and immunotherapeutic molecules which interact in subjects with insulin-dependent diabetes mellitus (IDDM)
EP0307513A3 (en) Pulmonary hydrophobic surfactant-associated proteins
CA2128215C (en) Autotaxin: motility stimulating protein useful in cancer diagnosis and therapy
HUT62327A (en) Process for producing somatotropins modified in their alfa-helix 1 region and their combination with other mutants
Herzbeck et al. Functional and Molecular Characterization of a Monoclonal Antibody against the 165–186 Peptide of Human 1β
WO1991010684A1 (en) Oxidized variants of gm-csf
ATE103979T1 (en) HUMAN LYMPHOTOXIN.
KR930701600A (en) Stable and Bioactive Modified Somatotropin
CA2083286A1 (en) Recombinant fibrinogenases, preparation and use thereof
Dukovich The Purification and Biochemical Characterization of Natural and Recombinant Interleukin 1

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19901113

FG3A Patent granted, date of granting

Effective date: 19970630

PC3A Transfer or assignment

Free format text: 19981117 DSM N.V. NL

MM3A Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20031231